Pyriform sinus fistula in children: A comparison of endoscopic-assisted surgery and endoscopic radiofrequency ablation

BackgroundPyriform sinus fistula (PSF) is a rare congenital anomaly, and the preferred definitive treatment is yet to be verified. In this study, we investigated the treatment outcomes of PSF specifically comparing endoscopic-assisted surgery and endoscopic radiofrequency ablation (RA).MethodsThe medical records of patients treated for PSF at the Shanghai Children's Hospital between October 2016 and September 2019 were retrospectively evaluated.ResultsThere were 93 girls and 98 boys. The median age at onset and operation was 3 years and 5 years, respectively. Endoscopic-assisted surgery was performed in 143 patients. During the same period, RA was performed in 48 patients, and 10 of them concurrently underwent incision and drainage of neck abscesses. Longer hospital stay was found in the endoscopic-assisted surgery group than in the RA group (10.50 ± 3.93 vs. 5.02 ± 3.30 days, P < 0.001). Postoperative complications were not significantly different between the two groups, except for neck infection (0 vs. 8.3%, P = 0.004). After a median follow-up period of 21 months, no significant difference was found between the two groups in terms of recurrence (1.4% vs. 0, P = 0.560).ConclusionPatients treated with RA had a significantly shorter hospital stay than those treated with endoscopic-assisted surgery. Outcomes of endoscopic-assisted surgery and RA were not significantly different for the management of PSF and treatment method should be tailored to the patient.Level of evidenceIV.     

Design and Simulation of Active Biochip System

To solve the problems existing in passive biochip systems, we designed a novel active biochip system. This system introduces negative pressure and controlling devices to adjust the antigen-antibody reaction on the nitrocellulose membrane. Computational simulation demonstrated that this system is a rapid, stable, robust and practical system that may enhance the efficiency of antigen-antibody reactions and improve the repeatability and accuracy of biochip analysis.     

玉屏风颗粒联合粉尘螨滴剂舌下脱敏治疗小儿变应性鼻炎肺脾气虚证临床研究

目的：观察玉屏风颗粒联合粉尘螨滴剂舌下脱敏治疗小儿变应性鼻炎肺脾气虚证的临床疗效。方 法：选择90 例变应性鼻炎肺脾气虚证患儿为研究对象,按随机数字表法分为观察组和对照组各45 例。对照组 给予粉尘螨滴剂舌下脱敏治疗,观察组在对照组基础上给予玉屏风颗粒冲服。1 周为1 个疗程,连续治疗6 个 疗程。比较2 组临床疗效、鼻部症状评分、体液免疫功能指标及炎性因子水平。结果：观察组总有效率为 97.78%,高于对照组86.67% （P＜0.05）。治疗后,2 组鼻塞、鼻痒、喷嚏、流涕评分均较治疗前降低（P＜ 0.05）,且观察组各项评分均低于对照组（P＜0.05）。治疗后,2 组血清免疫球蛋白M （IgM）、免疫球蛋白 G（IgG） 水平高于治疗前,免疫球蛋白E（IgE） 水平低于治疗前（P＜0.05）;且观察组IgM、IgG 水平高于对 照组,IgE 水平低于对照组（P＜0.05）。治疗后,2 组血清白细胞介素-4（IL-4）、白细胞介素-13（IL-13）、 血管细胞黏附因子-1（VCAM-1） 水平均较治疗前降低（P＜0.05）,且观察组血清IL-4、IL-13、VCAM-1 水 平均低于对照组（P＜0.05）。结论：玉屏风颗粒联合粉尘螨滴剂舌下脱敏治疗小儿变应性鼻炎肺脾气虚证的疗 效显著,有利于改善患儿临床症状,提高机体免疫力,减轻炎症反应。     

Laparoscopic Assisted Surgery for Crohn''''s Disease an Initial Experience and Results

SurgicaltreatmentisoftenrequiredforpatientswithCrohn'sdiseasewhohaveintestinalstrictureand/orfistula[4.1o.13].Rapidevolutionoflaparoscopicintestinalsurgery,continuousadvancementofinstru-mentation,performanceofmoreextensiveandcom-p1exprocedureshaveledtotheapplicationoflaparo-scopictechniquesinthetreatmentofCrohn'sdis-ease[3'9'12J.Recentreportshavedemonstratedthat,comparedwithtraditional"open"resection,laparo-scopicintestinalsurgeryresultsindecreasedpostoper-ativepain,earlierreturnofintestinalf…     

乌鲁木齐市2000-2004年法定传染病报告质量调查分析

目的为了及时准确地掌握各类传染病的漏报情况，为制订传染病防治策略提供理论依据。方法每年对区、市、系统、乡级医疗机构疫情报告情况进行调查，计算漏报率。结果共调查传染病患者4069例，漏报130例．总平均漏报率为3．19％。年漏报率最低为0．53％；最高为10．39％。漏报病种最高为细菌性痢疾和病毒性肝炎．分别占总漏报数的53．85％和26．15％。结论领导重视、提高业务人员的能力和基层防保队伍的建设，是传染病疫情报告和管理工作顺利开展的保证。     

德国健康保险与预防性医疗服务

德国社会医疗保险具有悠久的历史,早在1883年俾斯麦执政时就引入了强制性医疗保险并奠定了社会保障的基础。德国的基本法规定了社会医疗保险的团结互助原则,保证了每个参保人拥有相同的医疗保障, 这在法律上体现了公平合理的原则。从上世纪80年代至90 年代,德国经济一直处于高速发展的繁荣期,社会医疗保险     

信息技术与中药学课程整合之我见

为适应教学需要，更好地促进教与学，达到更深意义的教学互动、教学互长，笔者将信息技术与中药学课程相整合，其体会如下。     

血府逐瘀汤治疗髋关节置换术后非感染性发热

[目的]探讨髋关节置换术后非感染性发热的防治。[方法]应用血府逐瘀汤加减辨证论治。[结果]43例患者体温恢复正常,其中36例在3天内体温恢复正常。[结论]该方法对髋关节置换术后非感染性发热有较好作用。     

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.

PURPOSE: Effective and tolerable palliative treatments are needed for patients with incurable squamous cell carcinoma of the head and neck (SCCHN). Single-agent targeted therapies have limited activity in this setting. The feasibility of adding celecoxib to gefitinib for the treatment of incurable SCCHN is unknown. PATIENTS AND METHODS: Nineteen patients with unresectable recurrent locoregional and/or distant metastatic SCCHN with progressive disease after at least one prior chemotherapy or chemoradiotherapy regimen were enrolled onto this single-institution phase I study. Three dose levels were explored: (1) celecoxib 200 mg twice daily plus gefitinib 250 mg daily; (2) celecoxib 400 mg twice daily plus gefitinib 250 mg daily; and (3) celecoxib 400 mg twice daily plus gefitinib 500 mg daily. RESULTS: No dose-limiting toxicities were encountered at any dose level. The most common toxicities were acneiform rash, diarrhea, hand reaction, dyspepsia, and anemia. Four of 18 patients assessable for response (22%; 95% CI, 2% to 42%) achieved a confirmed partial response. CONCLUSION: The combination of gefitinib 500 mg daily plus celecoxib 400 mg twice daily is well-tolerated. The encouraging responses seen in this early study suggest further evaluation of epidermal growth factor receptor and cyclooxygenase-2 inhibitors in SCCHN is warranted.